By MICHAEL WAGNITZ
It’s now been almost three years since I wrote a column in The Capital Times about our ignoring of safety data concerning the use of the neurotoxin aluminum in vaccines. At that time there were no studies examining its use in childhood vaccines and the explosion in autism affecting our children. This has since changed.
In November, a group of scientists from the University of British Columbia published a paper in the Journal of Inorganic Biochemistry titled “Do aluminum vaccine adjuvants contribute to the rising prevalence of autism?”
Aluminum is used as an adjuvant in vaccines to provoke a strong immune response to the vaccine antigen. Aluminum-containing vaccines are administered at birth and again at 2, 4, 6, 12 and 18 months of age in the U.S. As both a neurotoxin and immune stimulator, aluminum is especially problematic when considering neuro-immune diseases such as autism. Aluminum vaccine adjuvants have been linked to a variety of adult autoimmune disorders such as Gulf War syndrome, yet newborns and infants are being exposed to much higher levels than adults. This is especially problematic when weight and blood volumes of infants are considered.